{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:25:16Z","timestamp":1778876716129,"version":"3.51.4"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo Europe GmbH"},{"name":"Faysal Riaz, PhD, of inScience Communications, Springer Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>This randomized, parallel\u2010group study in patients inadequately controlled on olmesartan medoxomil\/amlodipine (<jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>) 40\/10\u00a0mg assessed the effects of adding hydrochlorothiazide (<jats:styled-content style=\"fixed-case\">HCTZ<\/jats:styled-content>) 12.5\u00a0mg and 25\u00a0mg, using seated blood pressure (Se<jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>) measurements and ambulatory blood pressure (<jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>) monitoring. Enrolled patients were screened and tapered off of therapy if required. All\u00a0patients received <jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content> 40\/10\u00a0mg and those with\u00a0mean seated <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> (Se<jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>) \u2265140\/90\u00a0mm\u00a0Hg after 8\u00a0weeks (n=808) were randomized (1:1:1) to continue with\u00a0<jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content> 40\/10\u00a0mg or receive <jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">HCTZ<\/jats:styled-content> 40\/10\/12.5 or\u00a040\/10\/25\u00a0mg for a further 8\u00a0weeks. The primary endpoint was the change in seated diastolic <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> (Se<jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content>) from the start to the end of the randomized treatment period. The addition of <jats:styled-content style=\"fixed-case\">HCTZ<\/jats:styled-content> 25\u00a0mg significantly reduced Se<jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content> (\u22122.8\u00a0mm\u00a0Hg; <jats:italic>P<\/jats:italic>&lt;.0001), lowered seated systolic <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> (Se<jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>) and ambulatory <jats:styled-content style=\"fixed-case\">DBP<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">SBP<\/jats:styled-content>, and improved <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> goal rates. In patients uncontrolled on <jats:styled-content style=\"fixed-case\">OLM<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">AML<\/jats:styled-content> 40\/10\u00a0mg, adding <jats:styled-content style=\"fixed-case\">HCTZ<\/jats:styled-content> led to further <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content> reductions, particularly in ambulatory <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jch.12621","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T23:11:47Z","timestamp":1436915507000},"page":"60-69","source":"Crossref","is-referenced-by-count":5,"title":["Adding Hydrochlorothiazide to Olmesartan\/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual\u2010Combination Therapy"],"prefix":"10.1111","volume":"18","author":[{"given":"Lars C.","family":"Rump","sequence":"first","affiliation":[{"name":"Department of Nephrology Medical Faculty Heinrich\u2010Heine\u2010University D\u00fcsseldorf D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Ammentorp","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Laeis","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Scholze","sequence":"additional","affiliation":[{"name":"Outpatient Clinic\u2010Hypertension Excellence Centre ESH Universit\u00e4tsmedizin Berlin CHARIT\u00c9\u2010CCM Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.21.2805"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04311-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr080"},{"key":"e_1_2_8_7_1","first-page":"137","article-title":"ARB\u2010based single\u2010pill platform to guide a practical therapeutic approach to hypertensive patients","volume":"21","author":"Volpe M","year":"2014","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.07.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261919"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022273"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.02.014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61184-7"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00544.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328333146d"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0117-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.105"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/0044011-200929010-00002"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001267"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199816030-00004"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.03.679"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903251193"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902804158"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.487391"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802630588"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/08038020310000122"},{"key":"e_1_2_8_27_1","unstructured":"Committee for Medicinal Products for Human Use.Guideline on clinical development of fixed combination medicinal products.European Medicines Agency2008; CPMP\/EWP\/240\/95 Rev. 1:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003686.pdf. Accessed June 30 2015."},{"key":"e_1_2_8_28_1","unstructured":"Committee for Medicinal Products for Human Use.Guideline on clinical investigation of medicinal products in the treatment of hypertension.European Medicines Agency2009; CPMP\/EWP\/238\/95 Rev. 3:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/12\/WC500100191.pdf. Accessed June 30 2015."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.552426"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjch.12621","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jch.12621","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.12621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:40:58Z","timestamp":1695548458000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.12621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1111\/jch.12621"],"URL":"https:\/\/doi.org\/10.1111\/jch.12621","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}